Novo Nordisk announced plans to invest DKK 2.1 billion in a new 10,300 m2 facility in Hillerød, Denmark.
The facility will produce medicines for the treatment of diabetes and obesity. The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people.
Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes.
The investment in Hillerød underscores our long-term ambition to create and maintain jobs in Denmark. This year alone we have created 1,000 new jobs in Denmark, of which 500 are in production, primarily in Kalundborg and Hillerød, said Henrik Wulff, executive vice president and head of Product Supply, Novo Nordisk.
|Insulin Filling Facility
|DKK 2.1 Billion